Shai Policker
CEO
L
LifeCord
This startup develops a transfemoral mitral chordal repair system designed to treat mitral valve regurgitation. Their minimally invasive system preserves the leaflet without puncturing, offering an alternative to open-heart surgery for cardiovascular patients.
- Healthcare Technology
- Medical Devices
Updated 6 months ago
Funding
Funding rounds are not available yet.
Founders
Gal Atarot
Founder
Product
Problem
Mitral regurgitation, a common heart condition, often requires open-heart surgery, which carries significant risks and recovery time, especially for high-risk patients. Current treatment options may also involve leaflet puncturing, potentially complicating future interventions.
Solution
LifeCord is developing a transfemoral mitral chordal repair system designed to treat mitral valve regurgitation through a minimally invasive approach. The system aims to preserve the mitral valve leaflet without puncturing it, offering a less invasive alternative to open-heart surgery. This approach is intended to reduce regurgitation while allowing for future transcatheter interventions if needed. The technology initially targets high-risk patients who are not suitable candidates for traditional surgery, with the goal of expanding to a broader patient population as a first-line therapy.
Target Audience
The primary target audience includes high-risk cardiovascular patients with mitral regurgitation who are not eligible for open-heart surgery, as well as physicians specializing in cardiology and interventional cardiology.
Features
- Transfemoral delivery system for minimally invasive access to the mitral valve.
- Chordal repair mechanism designed to reduce mitral regurgitation.
- Leaflet-preserving design that avoids puncturing the valve tissue.
- Intended to allow for future transcatheter interventions.